Skip to main content

Clinical and Biomedical Sciences

Ms Claire Bewshea

Ms Claire Bewshea

Exeter IBD and Pharmacogenetics Project Manager

 cmb227@exeter.ac.uk

 01392 406850

 RILD Building L3/L06C

 

University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK


Overview

I am currently  working with Dr Tariq Ahmad, Consultant Gastroenterologist, Royal Devon and Exeter Hospital in delivering multi- centre NIHR  research projects in the field of Inflammatory Bowel Disease (IBD).

I graduated from University of Southampton in 1997 with a BSc (Hons) in  Pharmacology and Physiology. During my  time at Southampton  I also completed a industry placement with Bayer plc, and then went to work and train as a Clinical Research Scientist.   I then relocated to the South West and went on to work for  AstraZeneca until  2006.

From 2008 until 2011 I worked for NHS Devon as a Research and Clinical Trials Manager.

I have been working with Dr Tariq Ahmad since March 2011.

Qualifications

BSc (Hons) Pharmacology and Physiology 1997

Clinical Research Scientist 1998

Career

Boots 1988-1992

Bayer plc 1995-2002

Astrazeneca 2002-2006

NHS Devon 2008-2011

Links

Back to top


Research

Research interests

Inflammatory Bowel Disease Genetics of drug side effects anti-TNF response.

Research projects

5ASA - 5- AMINOSALICYLATE INDUCED NEPHROTOXICITY IN IBD PRED4 - Predicting Serious Drug Side Effects in Gastroenterology PANTS- Personalising Anti-TNF Therapy in Crohns Disease.

Research networks

National Institute for Health Research Royal Devon and Exeter Hospital Exeter CRF RD&E Blood Sciences British Society of Gastroenterology Crohn's and Colitis UK International Serious Adverse Event Consortium IBD GENETIC Consortium International IBD Genetics Consortium

Back to top


Publications

Journal articles

Carrieri D, Bewshea C, Walker G, Ahmad T, Bowen W, Hall A, Kelly SE (In Press). Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. Journal of Medical Ethics
Roberts C, Sazonovs A, Smith R, Bishara M, Lin S, Neil C, Bewshea C, Warden S, Pele L, Cocking L, et al (2024). OP11 Exploring the potential clinical utility of NUDT15 pharmacogenetic testing in clinical practice: a ‘focused reverse phenotyping’ study in the UK IBD Bioresource. Journal of Crohn's and Colitis, 18(Supplement_1), i19-i20.
Goodhand JR, Parkinson M, Bewshea C, Ahmad T, Kennedy NA (2024). P580 Iron deficiency anaemia and quality of life in Inflammatory Bowel Disease: Prospective cohort study of ferric derisomaltose on quality of life and work productivity in patients with IBD. Journal of Crohn's and Colitis, 18(Supplement_1), i1131-i1132.
Foyzul J, Alexander JL, Chappell KE, Ibraheim HA, Saifuddin A, Kennedy NA, Bewshea C, Lin S, Hart AL, Goodhand JR, et al (2024). P852 Metataxonomic and metabolomic profiling to predict response to anti-TNF therapy in Crohn’s Disease. Journal of Crohn's and Colitis, 18(Supplement_1), i1581-i1581.
Hanić M, Vučković F, Deriš H, Bewshea C, Lin S, Goodhand JR, Ahmad T, Trbojević-Akmačić I, Kennedy NA, Lauc G, et al (2023). Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease. Biomolecules, 13(6), 954-954. Abstract.
Liu Z, Alexander JL, Eng KY, Ibraheim H, Anandabaskaran S, Saifuddin A, Constable L, Seoane RC, Bewshea C, Nice R, et al (2023). Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib. J Crohns Colitis Abstract.  Author URL.
Bai BYH, Reppell M, Smaoui N, Waring JF, Pivorunas V, Guay H, Lin S, Chanchlani N, Bewshea C, Goodhand JR, et al (2023). Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn's disease patients. J Crohns Colitis Abstract.  Author URL.
Lin S, Hannon E, Waring JF, Reppell M, Smaoui N, Pivorunas VL, Guay H, Chanchlani N, Bewshea C, Bai BYH, et al (2023). DOP88 Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn’s disease. Journal of Crohn's and Colitis, 17(Supplement_1), i164-i166.
Baumdick ME, Niehrs A, Degenhardt F, Schwerk M, Hinrichs O, Jordan-Paiz A, Padoan B, Wegner LHM, Schloer S, Zecher BF, et al (2023). HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44<sup>+</sup> Natural Killer Cells in Ulcerative Colitis. Gastroenterology, 165(4), 946-962.e13. Abstract.
Liu Z, Alexander JL, Lin KW, VIP Study Investigators, Ahmad T, Pollock KM, Powell N (2023). Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine. Gastroenterology, 164(2), 300-303.e3. Author URL.
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, et al (2023). Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. Lancet Gastroenterol Hepatol, 8(2), 145-156. Abstract.  Author URL.
Liu Z, Alexander JL, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Lin KW, McFarlane LR, Constable L, et al (2023). Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study. eClinicalMedicine, 64 Abstract.
Liu Z, Le K, Zhou X, Alexander J, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald T, Lamb C, et al (2023). OP24 Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study. Journal of Crohn's and Colitis, 17(Supplement_1), i32-i34.
Liu Z, Alexander J, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Lin K, Mcfarlane L, Anand N, et al (2023). P535 COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy. Journal of Crohn's and Colitis, 17(Supplement_1), i664-i664.
Carbery I, Lin S, Chanchlani N, Janjua M, Nice R, McDonald TJ, Bewshea C, Kennedy NA, Ahmad T, Goodhand JR, et al (2023). P649 Does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn’s disease?. Journal of Crohn's and Colitis, 17(Supplement_1), i778-i778.
Lin S, Chanchlani N, Smith R, Roberts C, Nice R, McDonald TJ, Hamilton B, Bewshea C, Kennedy NA, Goodhand JR, et al (2023). P662 Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn’s disease. Journal of Crohn's and Colitis, 17(Supplement_1), i791-i793.
Chanchlani N, Lin S, Hamilton B, Bewshea C, Thomas A, Smith R, Roberts C, Nice R, McDonald TJ, Goodhand JR, et al (2023). P798 Understanding anti-TNF treatment failure: mechanisms and management of loss of response to anti-TNF therapy, three-year data from the PANTS study. Journal of Crohn's and Colitis, 17(Supplement_1), i928-i930.
Chanchlani N, Lin S, Smith R, Roberts C, Nice R, McDonald TJ, Hamilton B, Bishara M, Bewshea C, Kennedy NA, et al (2023). Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Naïve Patients with Active Luminal Crohn’s Disease. Crohn's & Colitis 360, 5(3). Abstract.
Alexander JL, Mullish BH, Danckert NP, Liu Z, Olbei ML, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Roberts LA, et al (2023). The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients. eBioMedicine, 88 Abstract.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, Davies M, McDonald TJ, Auckland C, Harries LW, et al (2023). Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Gut, 72(2), 295-305. Abstract.  Author URL.
Lin S, Hannon E, Reppell M, Waring JF, Smaoui N, Pivorunas V, Guay H, Chanchlani N, Bewshea C, Bai BYH, et al (2023). Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn's disease. J Crohns Colitis Abstract.  Author URL.
Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Arkir Z, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, et al (2022). Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. J Crohns Colitis, 16(3), 389-397. Abstract.  Author URL.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin K-M, Butler DK, et al (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun, 13(1). Abstract.  Author URL.
Baker S, Dougan G, Hess C, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Owehand WH, Saunders C, Summers C, et al (2022). Author Correction: SARS-CoV-2 evolution during treatment of chronic infection. Nature, 608(7922), e23-e23.
Baker S, Dougan G, Hess C, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Owehand WH, Saunders C, Summers C, et al (2022). Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 608(7922), e24-e24.
Alexander JL, Liu Z, Muñoz Sandoval D, Reynolds C, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Anand N, Nice R, et al (2022). COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol, 7(11), 1005-1015. Abstract.  Author URL.
Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Liu Z, Nice R, Bewshea C, D'Mello A, et al (2022). COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology & Hepatology, 7(4), 342-352.
Aggarwal D, Page AJ, Schaefer U, Savva GM, Myers R, Volz E, Ellaby N, Platt S, Groves N, Gallagher E, et al (2022). Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission. Nature Communications, 13(1).
Aggarwal D, Warne B, Jahun AS, Hamilton WL, Fieldman T, du Plessis L, Hill V, Blane B, Watkins E, Wright E, et al (2022). Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications, 13(1). Abstract.
Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, Seaman SR, Harris RJ, Hope R, Lopez-Bernal J, et al (2022). Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. The Lancet Infectious Diseases, 22(1), 35-42. Abstract.
Ellul P, Revés J, Abreu B, Chaparro M, Gisbert JP, Allocca M, Fiorino G, Barberio B, Zingone F, Pisani A, et al (2022). Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: an International Web-based Survey. Journal of Crohn's and Colitis, 16(7), 1070-1078. Abstract.
Alexander J, Kennedy N, Ibraheim H, Anandabaskaran S, Saifuddin A, Seoane RC, Liu Z, Nice R, Bewshea C, D’Mello A, et al (2022). OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab. Journal of Crohn's and Colitis, 16(Supplement_1), i022-i023.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, et al (2022). OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients. Journal of Crohn's and Colitis, 16(Supplement_1), i023-i025.
Ashford F, Best A, Dunn SJ, Ahmed Z, Siddiqui H, Melville J, Wilkinson S, Mirza J, Cumley N, Stockton J, et al (2022). SARS-CoV-2 Testing in the Community: Testing Positive Samples with the TaqMan SARS-CoV-2 Mutation Panel to Find Variants in Real Time. Journal of Clinical Microbiology, 60(4), e02408-e02421.
Alexander JL, Kennedy N, Ibraheim H, Anandabaskaran S, Saifuddin A, Seoane RC, Liu Z, Nice R, Bewshea CM, D'Mello A, et al (2022). Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB. Gastroenterology, 162(7).
Alexander JL, Mullish BH, Danckert NP, Liu Z, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Bewshea CM, Nice R, et al (2022). Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION. Gastroenterology, 162(7), s-652.
Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald TJ, Bewshea C, Kennedy NA, Ahmad T, Selinger CP, et al (2022). Understanding <scp>anti‐TNF</scp> treatment failure: does serum triiodothyronine‐to‐thyroxine (<scp>T3</scp>/<scp>T4</scp>) ratio predict therapeutic outcome to <scp>anti‐TNF</scp> therapies in biologic‐naïve patients with active luminal Crohn's disease?. Alimentary Pharmacology & Therapeutics, 56(5), 783-793. Abstract.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, et al (2021). Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 70(5), 865-875. Abstract.
Chapman TP, Revés J, Torres J, Satsangi J (2021). Anti–SARS-CoV-2 Antibody Responses in Patients with IBD Treated with Biologics: Are We Finding CLARITY?. Gastroenterology, 161(6), 2057-2059.
Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, Toole AO, et al (2021). Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. NATURE, 593(7858), 266-+. Author URL.
Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, Kläser K, Canas LS, Molteni E, Modat M, et al (2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. The Lancet Public Health, 6(5), e335-e345.
Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, Davis C, Piccoli L, Pascall DJ, Dillen J, et al (2021). Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 184(5), 1171-1187.e20.
Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O’Toole Á, Southgate J, Johnson R, Jackson B, Nascimento FF, et al (2021). Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell, 184(1), 64-75.e11.
Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Page AJ, et al (2021). Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science, 374(6574). Abstract.  Author URL.
Jackson B, Boni MF, Bull MJ, Colleran A, Colquhoun RM, Darby AC, Haldenby S, Hill V, Lucaci A, McCrone JT, et al (2021). Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell, 184(20), 5179-5188.e8.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, et al (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 70(10), 1884-1893. Abstract.  Author URL.
Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, Harvey WT, Lytras S, Mohamed A, Gallo G, et al (2021). Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 35(13). Abstract.
Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, et al (2021). SARS-CoV-2 evolution during treatment of chronic infection. Nature, 592(7853), 277-282. Abstract.
Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, et al (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. NATURE, 593(7857), 136-+. Author URL.
Reuken PA, Andreas N, Grunert PC, Glöckner S, Kamradt T, Stallmach A (2021). T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 16(2), 251-258. Abstract.
Nice R, Chanchlani N, Green H, Bewshea C, Ahmad T, Goodhand JR, McDonald TJ, Perry MH, Kennedy NA (2021). Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. Aliment Pharmacol Ther, 53(1), 128-137. Abstract.  Author URL.
Masoli JAH, Jeffries A, Temperton B, Auckland C, Michelsen M, Warwick-Dugdale J, Manley R, Farbos A, Ellard S, Knight B, et al (2021). Viral genetic sequencing identifies staff transmission of COVID-19 is important in a community hospital outbreak.  Abstract.
Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, et al (2020). HLA-DQA1*05 Carriage Associated with Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients with Crohn's Disease. Gastroenterology, 158(1), 189-199. Abstract.  Author URL.
Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, Walker G, Bewshea C, Kennedy NA, Ahmad T, et al (2020). Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterology, 12(6), 461-470. Abstract.
Nice R, Chanchlani N, Green H, Bewshea C, Kennedy N, Ahmad T, Goodhand J, McDonald T, Perry M (2020). OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: the prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service. Journal of Crohn's and Colitis, 14(Supplement_1), s018-s019.
Walker GJ, Chanchlani N, Thomas A, Lin S, Moore L, Heerasing NM, Hendy P, Abdelrahim M, Mole S, Perry MH, et al (2020). Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child, 105(10), 957-963. Abstract.  Author URL.
Walker GJ, Lin S, Chanchlani N, Thomas A, Hendy P, Heerasing N, Moore L, Green HD, Chee D, Bewshea C, et al (2020). Quality improvement project identifies factors associated with delay in IBD diagnosis. Alimentary Pharmacology & Therapeutics, 52(3), 471-480. Abstract.
Bewshea CM, Ahmad T, Kennedy N, Weedon M, Harrison J, Walker G, Goodhand J, Jones S (2019). Association of Genetic Variants in NUDT15 with Thiopurine-Induced Myelosuppression in Patients with Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 321 (8), 773-785.
Bewshea CM, Ahmad T, Kennedy N, Goodhand J, McDonald T, Green H (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterology and Hepatology
(2019). UEG Week 2019 Poster Presentations. United European Gastroenterology Journal, 7(S8), 189-1030.
Kennedy NA, Heap GA, Hamilton B, Walker GJ, Bewshea CM, Bouri S, Goodhand J, Consortium PI, Ahmad T (2018). 159 - Clinical Effectiveness, Safety and Immunogenicity of Anti-TNF Therapy in Crohn's Disease: 12 Month Data from the Pants Study. Gastroenterology, 154(6), s-44.
Walker GJ, Harrison JW, Voskuil MD, Heap GA, Heerasing N, Hendy PJ, Koskela J, Daly MJ, Sokol H, Weersma RK, et al (2018). 472 - NUDT15 Variants Contribute to Thiopurine-Induced Myelosuppression in European Populations. Gastroenterology, 154(6), s-111.
Sazonovs A, Kennedy NA, Bewshea CM, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). 590 - HLA-DQA1 Contributes to the Development of Antibodies to Anti-TNF Therapy in Crohn's Disease. Gastroenterology, 154(6).
Carrieri D, Jackson L, Bewshea C, Prainsack B, Mansfield J, Ahmad T, Hawkins N, Kelly S (2018). Ethical issues in genomic research: Proposing guiding principles co-produced with stakeholders. Clinical Ethics, 13(4), 194-198.
Walker GJ, Moore L, Heerasing N, Hendy P, Perry MH, McDonald TJ, Debenham T, Bethune R, Bewshea C, Hyde C, et al (2018). Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther, 47(8), 1103-1116. Abstract.  Author URL.
Sazonovs A, Kennedy N, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea C, Walker G, Perry MH, McDonald TJ, et al (2018). HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy.  Abstract.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Consortium PI, et al (2018). OP013 HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease. Journal of Crohn's and Colitis, 12(suppl_1), s9-s10.
Kennedy NA, Heap G, Hamilton B, Walker GJ, Bewshea C, Bouri S, Goodhand J, Consortium PI, Ahmad T (2018). OP031 Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study. Journal of Crohn's and Colitis, 12(suppl_1), s21-s21.
Walker G, Harrison J, Voskuil M, Heap G, Heerasing N, Hendy P, Koskela J, Daly M, Sokol H, McGovern D, et al (2018). OP035 NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations. Journal of Crohn's and Colitis, 12(supplement_1), s25-s26.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand J, Kennedy NA (2018). P793 Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance. Journal of Crohn's and Colitis, 12(suppl_1), s512-s513.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea CM, Ahmad T, Goodhand J, Kennedy NA (2018). Su1875 - Prevalence and Phenotype of Inflammatory Bowel Disease Across Primary and Secondary Care: Implications for Colorectal Cancer Surveillance. Gastroenterology, 154(6).
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Vito A, Beckly J, Buurman D, Chaudhary R, et al (2017). Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 11(12). Author URL.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, et al (2016). Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 10(2), 149-158. Abstract.  Author URL.
Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, et al (2015). Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics, 47(9), 979-986.
Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T (2015). Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Ann Clin Biochem, 52(Pt 6), 672-674. Abstract.  Author URL.
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). 6 Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants. Gastroenterology, 146(5), s-2.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 46(10), 1131-1134. Abstract.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet, 46(10), 1131-1134. Abstract.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 638 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease. Gastroenterology, 144(5), s-112.

Conferences

Chanchlani N, Lin S, Hamilton B, Bewshea C, Thomas A, Smith R, Roberts C, Nice R, McDonald T, Goodhand J, et al (2023). O59 Understanding anti-TNF treatment failure: mechanisms and management of loss of response to anti-TNF therapy, three-year data from the PANTS study. Oral presentations.
Smith R, Liu Z, Laskey K, Lin S, Chanchlani N, Nice R, Roberts C, Alexander J, McDonald TJ, Bewshea C, et al (2023). P115 Vitamin D concentrations are not associated with anti-SARS-CoV-2 antibody responses following mRNA COVID-19 vaccine in IBD patients treated with infliximab. Poster presentations.
Alexander J, Liu Z, Eng KY, Ibraheim H, Saifuddin A, Bewshea C, Balarajah S, Sebastian S, Irving P, Hicks L, et al (2023). P75 Vaccine-induced antibody responses against influenza are diminished in infliximab and tofacitinib-treated IBD patients and correlate with responses to COVID-19 vaccination. Poster presentations.
Liu Z, Alexander J, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Constable L, Bewshea C, Jones G, et al (2023). P77 Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type strain in patients with IBD after three doses of COVID-19 vaccine. Poster presentations.
Smith R, Lin S, Chanchlani N, Roberts C, Nice R, McDonald TJ, Hamilton B, Bewshea C, Kennedy NA, Goodhand JR, et al (2023). P82 Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn’s disease. Poster presentations.
Alexander J, Mullish B, Danckert N, Liu Z, Saifuddin A, Torkizadeh M, Ibraheim H, Miguens-Blanco J, Bewshea C, Nice R, et al (2022). P2 COVID-19 vaccination response in immunosuppressed patients with IBD is associated with altered gut microbiota function. Poster presentations.
Kennedy NA, Goodhand J, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft N, et al (2021). Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab.  Author URL.
Lin S, Bewshea C, Chanchlani N, Chee D, Pollok RC, Kennedy NA, Ahmad T, Goodhand JR (2021). Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic.  Author URL.
Nice R, Chanchlani N, Kennedy NA, Green HD, Lin S, Gordon C, Chee D, Hamilton B, Bewshea C, Goodhand J, et al (2021). POSITIVITY THRESHOLDS OF TOTAL INFLIXIMAB AND ADALIMUMAB ANTI-DRUG ANTIBODY ASSAYS AND IMPACT IN CLINICAL PRACTICE.  Author URL.
Nice R, Chanchlani N, Green H, Bewshea C, Kennedy N, Ahmad T, Goodhand J, McDonald T, Perry M (2020). Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: the prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service.  Author URL.
Walker G, Lin S, Thomas A, Chanchlani N, Moore L, Hendy P, Heerasing N, Green H, Mole S, Bewshea C, et al (2019). PROSPECTIVE COHORT TO IDENTIFY FACTORS ASSOCIATED WITH DIAGNOSTIC DELAY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.  Author URL.
Walker G, Lin S, Chanchlani N, Thomas A, Moore L, Hendy P, Heerasing N, Green H, Bewshea C, Goodhand J, et al (2019). Prospective cohort to identify factors associated with a delay in diagnosis in patients with inflammatory bowel disease.  Author URL.
Walker GJ, Harrison JW, Voskuil MD, Heap GA, Heerasing N, Hendy PJ, Koskela J, Daly MJ, Sokol H, Weersma RK, et al (2018). <i>NUDT15</i> VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.
Kennedy NA, Heap GA, Hamilton B, Walker GJ, Bewshea CM, Bouri S, Goodhand J, Ahmad T (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12 MONTH DATA FROM THE PANTS STUDY.  Author URL.
Kennedy N, Heap G, Walker G, Bewshea C, Bouri S, Goodhand J, Ahmad T (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12-MONTH DATA FROM PANTS.  Author URL.
Kennedy NA, Heap G, Hamilton B, Walker GJ, Bewshea C, Bouri S, Goodhand J, Ahmad T (2018). Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn's disease: 12-month data from the PANTS study.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand JR, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea CM, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's disease.  Author URL.
Walker G, Harrison J, Voskuil M, Heap G, Heerasing N, Hendy P, Koskela J, Daly M, Sokol H, McGovern D, et al (2018). NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations.  Author URL.
Hamilton B, Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand JR, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF IBD ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea CM, Ahmad T, Goodhand J, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF INFLAMMATORY BOWEL DISEASE ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand J, Kennedy NA (2018). Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance.  Author URL.
Hendy P, Heerasing N, Walker G, Heap G, Bewshea C, Kennedy N, Goodhand J, Harrower T, Hobart J, Spiers A, et al (2017). CLINICAL FEATURES OF DEMYELINATION DURING ANTI-TNF THERAPY: PRELIMINARY OUTCOMES OF THE PRED4 STUDY.  Author URL.
Walker GJ, Moore L, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Kennedy NA, Calvert C, Ahmad T (2017). CLINICAL VALIDITY AND UTILITY OF FAECAL CALPROTECTIN IN PRIMARY CARE.  Author URL.
Walker GJ, Harrison JW, Heap GA, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Weedon MN, Kennedy NA, Ahmad T, et al (2017). NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.
Walker G, Heap G, Bewshea C, Ahmad T, Irving P, Goodhand J (2016). ANTI-TNF PATIENT TREATMENT PREFERENCES: DATA FROM THE PANTS STUDY.  Author URL.
Heap G, Bewshea C, Singh A, Weedon M, Goldstein J, Ebney N, Mulgrew C, D'Souza R, Oram R, Orchard T, et al (2014). A genome wide association study identifying association of the MHC region with 5-aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease.  Author URL.
Heap GA, Singh A, Bewshea C, Weedon MN, Cole A, Creed T, Greig E, Irving P, Lindsay J, Mawdsley J, et al (2014). THIOPURINE INDUCED PANCREATITIS IN INFLAMMATORY BOWEL DISEASE: CLINICAL FEATURES AND GENETIC DETERMINANTS.  Author URL.
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants.  Author URL.
So K, Bewshea C, Heap GA, Muller AF, Daneshmend TK, Hart AL, Orchard TR, Irving PM, Russell RK, Wilson DC, et al (2013). 5-AMINOSALICYLATE (5-ASA) INDUCED NEPHROTOXICITY IN INFLAMMATORY BOWEL DISEASE.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease.  Author URL.

Back to top


Teaching

Pharmacology

Inflammatory Bowel Disease.

Back to top


Edit Profile